article thumbnail

Digital transformation can accelerate drug development and discovery process

Express Pharma

Ever-increasing drug discovery and development timelines are a multiscale issue causing delays in patient access to medicines and increasing costs for pharmaceutical companies.

article thumbnail

The Future of Partnerships in Generic Drug Development

Drug Patent Watch

The pharmaceutical industry is undergoing significant transformations, particularly in the realm of generic drug development. Recent trends and advancements in technology, research, and collaboration are reshaping the landscape of generic drug development, leading to new opportunities and challenges for pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030.

article thumbnail

STAT+: Gilead plans to halt free access to an HIV drug, worrying patient advocates

STAT

Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.

article thumbnail

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments. 

article thumbnail

Opinion: How Pfizer ended up passing on my GLP-1 work back in the early ’90s

STAT

To be clear, I’m not writing this to claim credit for discovery or development of GLP-1s or anything like that. Rather, I think the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. Read the rest…